Vontobel Holding Ltd. Sells 15,258 Shares of DexCom, Inc. (NASDAQ:DXCM)

Vontobel Holding Ltd. cut its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 43.6% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 19,766 shares of the medical device company's stock after selling 15,258 shares during the quarter. Vontobel Holding Ltd.'s holdings in DexCom were worth $1,350,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of DXCM. Norges Bank acquired a new position in shares of DexCom during the fourth quarter worth approximately $385,367,000. Woodline Partners LP bought a new stake in DexCom during the 4th quarter valued at $63,338,000. Northern Trust Corp raised its stake in DexCom by 22.2% during the 4th quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock valued at $322,454,000 after acquiring an additional 753,857 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of DexCom in the fourth quarter worth $41,295,000. Finally, GAMMA Investing LLC grew its stake in shares of DexCom by 5,951.7% in the first quarter. GAMMA Investing LLC now owns 499,746 shares of the medical device company's stock worth $34,128,000 after purchasing an additional 491,488 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Activity at DexCom

In other news, EVP Sadie Stern sold 6,184 shares of the company's stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total value of $526,320.24. Following the transaction, the executive vice president directly owned 109,621 shares of the company's stock, valued at approximately $9,329,843.31. This represents a 5.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction on Monday, June 16th. The stock was sold at an average price of $83.13, for a total value of $228,607.50. Following the sale, the director owned 56,621 shares of the company's stock, valued at approximately $4,706,903.73. This represents a 4.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 27,190 shares of company stock worth $2,281,732 in the last 90 days. 0.32% of the stock is owned by corporate insiders.

DexCom Trading Down 1.0%

Shares of NASDAQ:DXCM traded down $0.85 during mid-day trading on Friday, hitting $82.73. The stock had a trading volume of 1,841,055 shares, compared to its average volume of 4,400,961. The company's 50 day moving average is $83.26 and its 200-day moving average is $79.79. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $117.19. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.32 and a current ratio of 1.50. The company has a market cap of $32.44 billion, a PE ratio of 61.74, a P/E/G ratio of 1.77 and a beta of 1.44.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). The business had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a net margin of 12.90% and a return on equity of 30.05%. The company's revenue was up 12.5% compared to the same quarter last year. During the same period last year, the firm earned $0.32 EPS. On average, sell-side analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on DXCM shares. Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Mizuho began coverage on shares of DexCom in a research note on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price target for the company. The Goldman Sachs Group initiated coverage on shares of DexCom in a research note on Friday, May 30th. They set a "buy" rating and a $104.00 price objective on the stock. Cfra Research raised DexCom to a "hold" rating in a report on Friday, March 21st. Finally, Piper Sandler decreased their price target on DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. Five investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $98.50.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.